Published online before print August 18, 2005, doi: 10.1161/01.ATV.0000182904.08513.60
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2005 American Heart Association, Inc.
Atherosclerosis and Lipoproteins |
Associations Between Soluble CD40 Ligand, Atherosclerosis Risk Factors, and Subclinical Atherosclerosis
Results from the Dallas Heart Study
From the Donald W. Reynolds Cardiovascular Clinical Research Center (J.A.d.L., A.K., D.K.M., G.S., H.S.L., R.P.), University of Texas Southwestern Medical Center, Dallas, Tex; and the Donald W. Reynolds Cardiovascular Clinical Research Center (A.Z., U.S., N.V., S.A.M., R.N., D.A.M., P.L.), Brigham and Women’s Hospital, Boston Mass.
Correspondence to James A. de Lemos, MD, Division of Cardiology, UT Southwestern Medical Center, 5909 Harry Hines Blvd, Rm HA9.133, Dallas, TX 75390-9047. E-mail james.delemos{at}utsouthwestern.edu
Objectives— The purpose of this study was to evaluate the associations between plasma levels of soluble CD40 ligand (sCD40L), atherosclerosis risk factors, and evidence of subclinical atherosclerosis.
Methods and Results— Plasma levels of sCD40L were measured in 2811 subjects from the Dallas Heart Study, a multiethnic population-based cross-sectional study. Electron Beam Computed Tomography measurements of coronary artery calcium (CAC) and MRI measurements of aortic plaque were performed in 2198 and 1965 subjects, respectively. No association was observed between quartiles of sCD40L and age, sex, race, body mass index, diabetes, smoking, creatinine clearance, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, or C-reactive protein. In contrast, weak but statistically significant associations were observed between sCD40L and total cholesterol and triglycerides. The prevalence of detectable CAC (CAC score 
10) and aortic plaque did not differ across sCD40L quartiles, and individuals with CAC scores <10, 10 to 100, >100 to 400, and >400 had similar sCD40L levels.
Conclusions— In a large and representative multiethnic population-based sample, sCD40L was not associated with most atherosclerotic risk factors or with subclinical atherosclerosis. These findings suggest that sCD40L will not be useful as a tool to screen for the presence of subclinical atherosclerosis in the population. Further evaluation of this biomarker should focus on settings in which platelet activation is common, such as following acute coronary syndromes or coronary revascularization procedures.
Plasma levels of soluble CD40 ligand were not associated with most atherosclerotic risk factors or with subclinical atherosclerosis, suggesting limited utility in screening for subclinical atherosclerosis. Further evaluation of this biomarker should focus on settings where platelet activation is common, such as following acute coronary syndromes or coronary revascularization procedures.
Key Words: sCD40 ligand • CD40 • atherosclerosis • diabetes • cholesterol
This article has been cited by other articles:
 |
|
 |
|
  A. Rohatgi, A. W. Owens, A. Khera, C. R. Ayers, K. Banks, S. R. Das, J. D. Berry, D. K. McGuire, and J. A. de Lemos Differential Associations Between Soluble Cellular Adhesion Molecules and Atherosclerosis in the Dallas Heart Study: A Distinct Role for Soluble Endothelial Cell-Selective Adhesion Molecule Arterioscler Thromb Vasc Biol, October 1, 2009; 29(10): 1684 - 1690. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Khera, G. L. Vega, S. R. Das, C. Ayers, D. K. McGuire, S. M. Grundy, and J. A. de Lemos Sex Differences in the Relationship between C-Reactive Protein and Body Fat J. Clin. Endocrinol. Metab., September 1, 2009; 94(9): 3251 - 3258. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Natal, P. Restituto, C. Inigo, I. Colina, J. Diez, and N. Varo The Proinflammatory Mediator CD40 Ligand Is Increased in the Metabolic Syndrome and Modulated by Adiponectin J. Clin. Endocrinol. Metab., June 1, 2008; 93(6): 2319 - 2327. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. R. S. Packard and P. Libby Inflammation in Atherosclerosis: From Vascular Biology to Biomarker Discovery and Risk Prediction Clin. Chem., January 1, 2008; 54(1): 24 - 38. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Ferro, L. Loffredo, L. Polimeni, F. Fimognari, P. Villari, P. Pignatelli, V. Fuster, and F. Violi Soluble CD40 Ligand Predicts Ischemic Stroke and Myocardial Infarction in Patients With Nonvalvular Atrial Fibrillation Arterioscler Thromb Vasc Biol, December 1, 2007; 27(12): 2763 - 2768. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Zirlik, S. M. Abdullah, N. Gerdes, L. MacFarlane, U. Schonbeck, A. Khera, D. K. McGuire, G. L. Vega, S. Grundy, P. Libby, et al. Interleukin-18, the Metabolic Syndrome, and Subclinical Atherosclerosis: Results From the Dallas Heart Study Arterioscler Thromb Vasc Biol, September 1, 2007; 27(9): 2043 - 2049. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. von Hundelshausen and C. Weber Platelets as Immune Cells: Bridging Inflammation and Cardiovascular Disease Circ. Res., January 5, 2007; 100(1): 27 - 40. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.-K. L. Robertson and G. K Hansson T Cells in Atherogenesis: For Better or For Worse? Arterioscler Thromb Vasc Biol, November 1, 2006; 26(11): 2421 - 2432. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Malarstig, B. Lindahl, L. Wallentin, and A. Siegbahn Soluble CD40L Levels Are Regulated by the -3459 A>G Polymorphism and Predict Myocardial Infarction and the Efficacy of Antithrombotic Treatment in Non-ST Elevation Acute Coronary Syndrome Arterioscler Thromb Vasc Biol, July 1, 2006; 26(7): 1667 - 1673. [Abstract] [Full Text] [PDF]
|
|